Organon & Co (OGN)
18.54
+0.12
(+0.68%)
USD |
NYSE |
Apr 26, 16:00
18.54
0.00 (0.00%)
After-Hours: 20:00
Organon Cash from Financing (TTM): -569.00M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -569.00M |
September 30, 2023 | -574.00M |
June 30, 2023 | -573.00M |
March 31, 2023 | -668.00M |
December 31, 2022 | -433.00M |
September 30, 2022 | -182.00M |
June 30, 2022 | -123.00M |
Date | Value |
---|---|
March 31, 2022 | 293.00M |
December 31, 2021 | -977.00M |
September 30, 2021 | -1.823B |
June 30, 2021 | -2.108B |
March 31, 2021 | -2.918B |
December 31, 2020 | -2.175B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.918B
Minimum
Mar 2021
293.00M
Maximum
Mar 2022
-986.92M
Average
-574.00M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Merck & Co Inc | -4.81B |
Alnylam Pharmaceuticals Inc | 172.13M |
Amgen Inc | 21.05B |
Biogen Inc | -246.90M |
Pacira BioSciences Inc | -183.03M |